References
- Eichenauer DA, Engert A. Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management. Hematol Am Soc Hematol Educ Progr [Internet]. 2017 Dec 10;2017:324–328. http://www.ncbi.nlm.nih.gov/pubmed/29222274
- Tedoldi S, Mottok A, Ying J, et al. Selective loss of B-cell phenotype in lymphocyte predominant Hodgkin lymphoma. J Pathol. 2007;213(4):429–440. doi:10.1002/path.2242
- Brune V, Tiacci E, Pfeil I, et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med Internet. 2008 sep 17;205:2251–2268. http://www.ncbi.nlm.nih.gov/pubmed/18794340
- Thurner L, Hartmann S, Fadle N, et al. Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma. Nat Commun Internet. 2020 may 20;11:2465. http://www.ncbi.nlm.nih.gov/pubmed/32424289
- Kuppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A Internet. 1994 Nov 08;91:10962–10966. http://www.ncbi.nlm.nih.gov/pubmed/7971992
- Braeuninger A, Küppers R, Strickler JG, et al. Hodgkin and Reed–Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci. 1997;94(17):9337–9342. doi: 10.1073/pnas.94.17.9337
- Churchill HRO, Roncador G, Warnke RA, et al. Programmed death 1 expression in variant immunoarchitectural patterns of nodular lymphocyte predominant Hodgkin lymphoma: comparison with CD57 and lymphomas in the differential diagnosis. Hum Pathol. 2010;41(12):1726–1734. doi: 10.1016/j.humpath.2010.05.010
- Sattarzadeh A, Visser L, Rutgers B, et al. Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma. Int J Mol Sci. 2016;17(12):2127. doi: 10.3390/ijms17122127
- Bein J, Thurner L, Hansmann M, et al. Lymphocyte predominant cells of nodular lymphocyte predominant Hodgkin lymphoma interact with rosetting T cells in an immunological synapse. Am J Hematol. 2020;95(12):1495–1502. doi: 10.1002/ajh.25972
- Fan Z, Natkunam Y, Bair E, et al. Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol Internet. 2003 Sep 26;27:1346–1356. http://www.ncbi.nlm.nih.gov/pubmed/14508396
- Hartmann S, Doring C, Vucic E, et al. Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma. Br J Haematol Internet. 2015 Feb 04;169:415–422. http://www.ncbi.nlm.nih.gov/pubmed/25644177
- Hartmann S, Schuhmacher B, Rausch T, et al. Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma. Leukemia. 2016;30(4):844–853. doi: 10.1038/leu.2015.328
- Schuhmacher B, Bein J, Rausch T, et al. JUNB, DUSP2, SGK1,SOCS1 and CREBBP are frequently mutated in T-cell/histiocyte-rich large B-cell lymphoma. Haematologica. 2019;104(2):330–337. doi: 10.3324/haematol.2018.203224
- Posthuma HLA, Zijlstra JM, Visser O, et al. Primary therapy and survival among patients with nodular lymphocyte‐predominant Hodgkin lymphoma: a population‐based analysis in the Netherlands, 1993–2016. Br J Haematol. 2020;189(1):117–121. doi: 10.1111/bjh.16290
- Eichenauer DA, Plütschow A, Fuchs M, et al. Long-term follow-up of patients with nodular lymphocyte-predominant Hodgkin lymphoma treated in the HD7 to HD15 trials: a report from the German Hodgkin study group. J Clin Oncol. 2020;38(7):698–705. doi: 10.1200/JCO.19.00986
- Biasoli I, Stamatoullas A, Meignin V, et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer. 2009 Dec 24 2010;116:631–639. http://www.ncbi.nlm.nih.gov/pubmed/20029973
- Al-Mansour M, Connors JM, Gascoyne RD, et al. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin’s lymphoma. J Clin Oncol Internet. 2010 Jan 06;28:793–799. http://www.ncbi.nlm.nih.gov/pubmed/20048177
- Kalashnikov I, Tanskanen T, Pitkäniemi J, et al. Transformation and outcome of nodular lymphocyte predominant Hodgkin lymphoma: a Finnish Nationwide population-based study. Blood Cancer J. 2021;11(12):203. doi: 10.1038/s41408-021-00586-1
- Campo E, Jaffe ES, Cook JR, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140(11):1229–1253. doi: 10.1182/blood.2022015851
- Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. doi: 10.1038/s41375-022-01620-2
- Eichenauer DA, Plütschow A, Fuchs M, et al. Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin study group. J Clin Oncol. 2015;33(26):2857–2862. doi: 10.1200/JCO.2014.60.4363
- Chen RC, Chin MS, Ng AK, et al. Early-stage, lymphocyte-predominant Hodgkin’s lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol. 2009 Nov 26 2010;28:136–141. http://www.ncbi.nlm.nih.gov/pubmed/19933914
- Pinnix CC, Milgrom SA, Cheah CY, et al. Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood Adv Internet. 2019 may 01;3:1356–1367. http://www.ncbi.nlm.nih.gov/pubmed/31036721
- Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood Internet. 2011 Aug 11;118:4363–4365. http://www.ncbi.nlm.nih.gov/pubmed/21828141
- Eichenauer DA, Plutschow A, Fuchs M, et al. Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group. Leukemia. 2019 Oct 23 2020;34:953–956. http://www.ncbi.nlm.nih.gov/pubmed/31636342
- Appel BE, Chen L, Buxton AB, et al. Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: a Report from the Children’s Oncology Group. J Clin Oncol Internet. 2016 May 18;34:2372–2379. http://www.ncbi.nlm.nih.gov/pubmed/27185849
- Eichenauer DA, Engert A. How I treat nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2020;136(26):2987–2993. doi: 10.1182/blood.2019004044
- Shankar A, Hall GW, McKay P, et al. Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma — All <scp>St AGE s </scp>: a consensus‐based position paper from the Hodgkin lymphoma subgroup of the <scp>UK</scp> National Cancer Research Institute. Br J Haematol. 2022;197:679–690. doi: 10.1111/bjh.18169
- Eichenauer DA, Aleman BMP, André M, et al. Hodgkin lymphoma: eSMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv19–iv29. doi: 10.1093/annonc/mdy080
- Ballas LK, Metzger ML, Milgrom SA, et al. Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria. Leuk Lymphoma. 2021;62(5):1057–1065. doi: 10.1080/10428194.2020.1852559
- Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys Internet. 2014 Jun 25;89:854–862. http://www.ncbi.nlm.nih.gov/pubmed/23790512
- Savage KJ, Skinnider B, Al-Mansour M, et al. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood Internet. 2011 Aug 30;118:4585–4590. http://www.ncbi.nlm.nih.gov/pubmed/21873543
- Binkley MS, Rauf MS, Milgrom SA, et al. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood Internet. 2020 Mar 27;135:2365–2374. http://www.ncbi.nlm.nih.gov/pubmed/32211877
- Garciaz S, Harel S, Amorim S, et al. Rituximab-ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy. Br J Haematol. 2015 Dec 20 2016;175:735–737. http://www.ncbi.nlm.nih.gov/pubmed/26685097.
- Pugliese N, Picardi M, Della Pepa R, et al. Rituximab-containing risk-adapted treatment strategy in nodular lymphocyte predominant Hodgkin lymphoma: 7-years follow-up. Cancers (Basel). 2021;13(8):1760. doi: 10.3390/cancers13081760
- Borchmann S, Joffe E, Moskowitz CH, et al. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood Internet. 2019 Feb 17;133:2121–2129. http://www.ncbi.nlm.nih.gov/pubmed/30770396
- Xing KH, Connors JM, Lai A, et al. Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. Blood Internet. 2014 Apr 10;123:3567–3573. http://www.ncbi.nlm.nih.gov/pubmed/24713929
- Fanale MA, Cheah CY, Rich A, et al. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood Internet. 2017 May 20;130:472–477. http://www.ncbi.nlm.nih.gov/pubmed/28522441
- Gotti M, Sciarra R, Pulsoni A, et al. Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: a Study by Fondazione Italiana Linfomi. Hemasphere. 2023;7(4):e837. doi: 10.1097/HS9.0000000000000837
- Prusila REI, Haapasaari KM, Marin K, et al.R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphomaActa Oncol (Madr) Internet. 2018 Mar 15;1–3. http://www.ncbi.nlm.nih.gov/pubmed/29537344
- Eichenauer DA, Bühnen I, Baues C, et al. Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies. Blood. 2023. doi: 10.1182/blood.2023019939
- Cheng PTM, Villa D, Tonseth RP, et al. Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach. Blood Adv. 2021;5:3647–3655. doi: 10.1182/bloodadvances.2021004375
- Eichenauer DA, Kreissl S, Bühnen I, et al. PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study. Ann Oncol. 2021;32(6):807–810. doi: 10.1016/j.annonc.2021.02.018
- Hartmann S, Soltani AS, Bankov K, et al. Tumour cell characteristics and microenvironment composition correspond to clinical presentation in newly diagnosed nodular lymphocyte‐predominant Hodgkin lymphoma. Br J Haematol. 2022;199(3):382–391. doi: 10.1111/bjh.18376
- Eichenauer DA, Bühnen I, Kreissl S, et al. Histopathological growth patterns in patients with advanced nodular lymphocyte‐predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group. Br J Haematol. 2022;196(1):99–104. doi: 10.1111/bjh.17770
- Hartmann S, Eichenauer DA, Plutschow A, et al. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood Internet. 2013 Oct 09;122:4246–4252. http://www.ncbi.nlm.nih.gov/pubmed/24100447
- Shankar AG, Kirkwood AA, Hall GW, et al. Childhood and Adolescent nodular lymphocyte predominant Hodgkin lymphoma - a review of clinical outcome based on the histological variants. Br J Haematol Internet. 2015 Jun 27;171:254–262. http://www.ncbi.nlm.nih.gov/pubmed/26115355
- Untanu RV, Back J, Appel B, et al. Variant histology, IgD and CD30 expression in low-risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2018;65(1):e26753. doi: 10.1002/pbc.26753
- Eichenauer DA, Plutschow A, Schroder L, et al. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. Blood Internet. 2018 Aug 02;132:1519–1525. http://www.ncbi.nlm.nih.gov/pubmed/30064977
- Strati P, Cheng PTM, Steiner RE, et al. Outcome of relapsed and refractory nodular lymphocyte‐predominant Hodgkin lymphoma: a North American analysis. Br J Haematol. 2021;192(3):560–567. doi: 10.1111/bjh.17281
- Hartmann S, Plutschow A, Mottok A, et al. The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma. Am J Hematol Internet. 2019 Aug 10;94:1208–1213. http://www.ncbi.nlm.nih.gov/pubmed/31396979
- Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2007 oct 17 2008;111:109–111. http://www.ncbi.nlm.nih.gov/pubmed/17938252
- Eichenauer DA, Goergen H, Plutschow A, et al. Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group. Leukemia.2015 Nov 21 2016;30:1425–1427. http://www.ncbi.nlm.nih.gov/pubmed/26585412
- Eichenauer DA, Bühnen I, Plütschow A, et al. Phase II study of fixed‐duration single‐agent ibrutinib in relapsed nodular lymphocyte‐predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Hematol Oncol. 2022;40(4):801–804. doi: 10.1002/hon.2986
- Haas RL, Girinsky T, Aleman BM, et al.Low-dose involved-field radiotherapy as alternative treatment of nodular lymphocyte predominance Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys Internet. 2009 01 oct;74:1199–1202. http://www.ncbi.nlm.nih.gov/pubmed/19131186
- Akhtar S, Montoto S, Boumendil A, et al. High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: a retrospective study by the European society for blood and marrow transplantation-lymphoma working party. Am J Hematol. 2017 oct 4 2018;93:40–46. http://www.ncbi.nlm.nih.gov/pubmed/28971503
- Karuturi M, Hosing C, Fanale M, et al. High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma. Biol Blood Marrow Transplant Internet. 2013 20 mar;19:991–994. http://www.ncbi.nlm.nih.gov/pubmed/23507470
- Kenderian SS, Habermann TM, Macon WR, et al. Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institutionBloodInternet. 2016 02 apr;127:1960–1966. http://www.ncbi.nlm.nih.gov/pubmed/26837698
- Eyre TA, Gatter K, Collins GP, et al. Incidence, management, and outcome of high-grade transformation of nodular lymphocyte predominant Hodgkin lymphoma: long-term outcomes from a 30-year experience. Am J Hematol Internet. 2015 Feb 27;90:E103–10. http://www.ncbi.nlm.nih.gov/pubmed/25715900
- Panjwani PK, Charu V, DeLisser M, et al. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes. Hum Pathol. 2018;71:91–99. doi:10.1016/j.humpath.2017.10.029